AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

This trial is a Phase Ib/II study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and AK104 with or without chemotherapy in subjects with advanced NSCLC.

Study Overview

• Status: Active, not recruiting
• Conditions: Advanced Non-small-cell Lung Cancer
• Intervention / Treatment: Drug: AK112; Drug: AK104; Drug: paclitaxel; Drug: pemetrexed; Drug: Docetaxel; Drug: Carboplatin

• Study Type: Interventional
• Enrollment (Estimated): 233
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai, China
    • Shanghai Pulmonary Hospital
  • Zhejiang
    • Hangzhou, Zhejiang, China
      • Zhejiang Cancer Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Has a histologically or cytologically confirmed diagnosis of NSCLC.
• Has Stage IIIB/C or IV NSCLC (American Joint Committee on Cancer [AJCC 8th]).
• 18-75 years old (at the time consent is obtained).
• Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
• Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.
• Has a life expectancy of at least 3 months.
• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team.
• Has no EGFR-sensitive mutations or ALK gene translocations.
• Has adequate organ function.
• Has recovered from the effects of any prior radiotherapy or surgery.
• All female and male subjects of reproductive potential must agree to use an effective method of contraception, during and for 120 days after the last dose of study treatment.

Exclusion Criteria:

• Has any histologically small cell carcinoma component.
• Is currently participating in a study of an investigational agent or using an investigational device.
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment.
• Has undergone major surgery within 30 days of Study Day 1.
• Has a known additional malignancy that is progressing or requires systemic treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
• Has known active central nervous system (CNS) metastases.
• Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
• Has an active infection requiring systemic therapy.
• Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
• Has a history of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator.
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
• Has received a live virus vaccine within 30 days of the planned first dose of study therapy.
• Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: docetaxel	Drug: Docetaxel; Subjects receive docetaxel intravenously.
Experimental: AK112 plus AK104	Drug: AK112; Subjects receive AK112 intravenously.; Drug: AK104; Subjects receive AK104 intravenously.
Experimental: AK112, AK104 plus docetaxel	Drug: AK112; Subjects receive AK112 intravenously.; Drug: AK104; Subjects receive AK104 intravenously.; Drug: Docetaxel; Subjects receive docetaxel intravenously.
Experimental: AK112, AK104 dose 1 plus carboplatin and paclitaxel	Drug: AK112; Subjects receive AK112 intravenously.; Drug: AK104; Subjects receive AK104 intravenously.; Drug: paclitaxel; Subjects receive paclitaxel intravenously.; Drug: Carboplatin; Subjects receive carboplatin intravenously.
Experimental: AK112, AK104 dose 1 plus carboplatin and pemetrexed	Drug: AK112; Subjects receive AK112 intravenously.; Drug: AK104; Subjects receive AK104 intravenously.; Drug: pemetrexed; Subjects receive pemetrexed intravenously.; Drug: Carboplatin; Subjects receive carboplatin intravenously.
Experimental: AK112, AK104 dose 2 plus carboplatin and paclitaxel	Drug: AK112; Subjects receive AK112 intravenously.; Drug: AK104; Subjects receive AK104 intravenously.; Drug: paclitaxel; Subjects receive paclitaxel intravenously.; Drug: Carboplatin; Subjects receive carboplatin intravenously.
Experimental: AK112, AK104 dose 2 plus carboplatin and pemetrexed	Drug: AK112; Subjects receive AK112 intravenously.; Drug: AK104; Subjects receive AK104 intravenously.; Drug: pemetrexed; Subjects receive pemetrexed intravenously.; Drug: Carboplatin; Subjects receive carboplatin intravenously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety reflected by AE	Safety will be reflected by AE, which is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.	Up to 2 approximately years
ORR per RECIST v1.1	ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1.	Up to 2 approximately years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS	Overall Survival (OS) is defined as the time from the start of treatment with AK112 until death due to any cause.	Up to 2 approximately years
ADA	Number of subjects with detectable anti-drug antibodies (ADA).	Up to 2 approximately years
DoR per RECIST v1.1	Duration of response (DoR) assessed according to RECIST v1.1.	Up to 2 approximately years
DCR per RECIST v1.1	Disease control rate (DCR) assessed according to RECIST v1.1.	Up to 2 approximately years
TTR per RECIST v1.1	Time to response (TTR) is defined as the time to response base on RECIST v1.1.	Up to 2 approximately years
PFS per RECIST v1.1	Progression-free survival (PFS) is defined as the time from the date of Initial administration till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first).	Up to 2 approximately years
AK112 serum concentration	The serum concentration of AK112 of individual subjects at different time points.	Up to 2 approximately years
AK104 serum concentration	The serum concentration of AK104 of individual subjects at different time points.	Up to 2 approximately years
PD-L1 expression	The correlationship between PD-L1 expression and efficacy.	Up to 2 approximately years
ctDNA	The correlationship between ctDNA detection and efficacy.	Up to 2 approximately years

Collaborators and Investigators

• Sponsor: Akeso

Study record dates

Study Major Dates

• Study Start (Actual): July 13, 2023
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): January 31, 2027

Study Registration Dates

• First Submitted: May 17, 2023
• First Submitted That Met QC Criteria: June 6, 2023
• First Posted (Actual): June 15, 2023

Study Record Updates

• Last Update Posted (Actual): March 9, 2026
• Last Update Submitted That Met QC Criteria: March 5, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Amino Acids, Peptides, and Proteins; Organic Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Coordination Complexes; Guanine; Hypoxanthines; Purinones; Purines; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Dicarboxylic; Taxoids; Cyclodecanes; Diterpenes; Docetaxel; Pemetrexed; Carboplatin; Paclitaxel
• Other Study ID Numbers: AK112-208

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No